Loading
Life sciences · Phase 2/3 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2/3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04402788). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: SUSPENDED. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 138 participants (ESTIMATED). Conditions: Extensive Stage Lung Small Cell Carcinoma. Interventions: DRUG: Atezolizumab; PROCEDURE: Biospecimen Collection; PROCEDURE: Computed Tomography; PROCEDURE: Magnetic Resonance Imaging; PROCEDURE: Positron Emission Tomography; RADIATION: Radiation Therapy. Primary outcome measures: Progression-free survival (PFS) (Phase II) , From randomization to any documented progression or death due to any cause, whichever occurs first, assessed up to 6 years; Overall survival (OS) (Phase III) , From randomization to the date of death due to any cause, assessed up to 6 years. Brief summary: This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.